ArticleCancer reports (Hoboken, N.J.)2025
Development of a Machine Learning Model Integrating Pathomics and Clinical Data to Predict Axillary Lymph Node Metastasis in Breast Cancer: A Two-Center Study.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Development of a Machine Learning Model Integrating Pathomics and Clinical Data to Predict Axillary Lymph Node Metastasis in Breast Cancer: A Two-Center Study.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAccurately assessing the status of axillary lymph nodes (ALNs) is essential for devising optimal surgical plans and making informed treatment decisions in breast cancer (BC) patients.
aimsThis study aims to develop an innovative nomogram based on pathomics to preoperatively predict ALN metastasis (ALNM) in BC. METHODS AND
resultsOur study performed a retrospective analysis on digital hematoxylin and eosin (H&E)-stained images obtained from 407 patients across two institutions who were allocated into a training cohort (TC; n = 203), an internal validation cohort (IVC; n = 136), and an external validation cohort (EVC; n = 68). Initially, the Mann-Whitney U-test and Spearman's rank correlation coefficient were utilized for feature selection, employing the least absolute shrinkage and selection operator (LASSO) regression for further refinement. For the evaluation of the predictive value of ALNM and other clinicopathological factors, we deployed both univariate (ULR) and multivariate (MLR) logistic regression analyses. Among the six machine learning (ML) algorithms, logistic regression, which demonstrated the highest area under the curve (AUC) value, was employed to establish the final nomogram model. The nomogram reliability and stability were assessed by analyzing the AUC of the receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and calibration plots. MLR analysis demonstrated estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), tumor size, and pathomics features as independent ALNM predictors. The nomogram demonstrated that the AUC in the IVC (0.783) surpassed that of the Path-score model (0.698) (DeLong test, p = 0.008558). Similarly, in the EVC, the nomogram surpassed the clinical model regarding AUC (0.738 vs. 0.574; DeLong test, p = 0.00494). Additionally, DCA analysis indicated a net clinical benefit associated with the nomogram.
conclusionOur study demonstrates the effectiveness of pathomics features in predicting ALNM in BC patients. Furthermore, the pathomics-based nomogram offers a valuable tool for personalized treatment planning in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.